Accordingly, in vivo subcutaneous xenograft modeling of mut-p53 demonstrated R273C-p53 expression decreased tumor-free survival compared to R273H-p53, defined as the time until the tumor reached 100 mm3 or castration surgery was performed (100–150 mm3; Fig. 7C). The gene discussed is TP53; the disease is neoplasm.